Néphropathie diabétique : traitements émergents

Gueutin, Victor; Gauthier, Marion; Cazenave, M.; Izzedine, Hassane

doi:10.1016/j.nephro.2014.02.004

Cited by 3 publications

(2 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on these results, more studies are still needed for the evaluation of the possible synergistic effects of silymarin with other antidiabetic classes (e.g., biguanides/metformin, dipeptidyl peptidase-4 inhibitors/sitagliptin; glucagon-like peptide-1 analogues/liraglutide; sodium-glucose cotransporter 2 inhibitors/dapagliflozin). Interestingly, silymarin has also been demonstrated to be an alternative treatment for diabetic renal patients who are using the maximum doses of angiotensin-converting enzyme (ACE) inhibitors or AT1 antagonists; even after a short duration treatment with silymarin (420 mg/day, for 12 weeks), these patients showed a reduction of 50% in albuminuria, urinary TNFα levels besides serum and urinary lipid peroxidation [156,157], which reflects a potential nephroprotective activity.…”

Section: Potential Of Natural Products With Antioxidant Effects Fomentioning

confidence: 99%

Coadjuvants in the Diabetic Complications: Nutraceuticals and Drugs with Pleiotropic Effects

Pereira

Pimenta

Porto

et al. 2016

IJMS

View full text Add to dashboard Cite

Because diabetes mellitus (DM) is a multifactorial metabolic disease, its prevention and treatment has been a constant challenge for basic and clinical investigators focused on translating their discoveries into clinical treatment of this complex disorder. In this review, we highlight recent experimental and clinical evidences of potential coadjuvants in the management of DM, such as polyphenols (quercetin, resveratrol and silymarin), cultured probiotic microorganisms and drugs acting through direct/indirect or pleiotropic effects on glycemic control in DM. Among several options, we highlight new promising therapeutic coadjuvants, including chemical scavengers, the probiotic kefir and the phosphodiesterase 5 inhibitors, which besides the reduction of hyperglycemia and ameliorate insulin resistance, they reduce oxidative stress and improve endothelial dysfunction in the systemic vascular circulation. In the near future, experimental studies are expected to clear the intracellular pathways involving coadjuvants. The design of clinical trials may also contribute to new strategies with coadjuvants against the harmful effects of diabetic complications.

show abstract

Section: Potential Of Natural Products With Antioxidant Effects Fomentioning

confidence: 99%

Coadjuvants in the Diabetic Complications: Nutraceuticals and Drugs with Pleiotropic Effects

Pereira

Pimenta

Porto

et al. 2016

IJMS

View full text Add to dashboard Cite

show abstract

“…Diabetic nephropathy (DN) is one of the major microvascular complications of diabetes and has become the leading cause of end-stage renal disease (ESRD) (1,2). DN is also a major cause of morbidity and mortality in patients with diabetes due to the progression to ESRD and associated cardiovascular disease (3,4).…”

Section: Introductionmentioning

confidence: 99%

The Therapeutic Effects of Sevelamer on Blood Sugar, HbA1c, Lipid Profile, and hs-CRP in Patients with Diabetic Nephropathy

Kebar¹,

Shargi²,

Bashardoust³

et al. 2018

J Nephropathol

View full text Add to dashboard Cite

Background: Diabetic nephropathy (DN) is one of the major complications of diabetes. Hyperglycemia, inflammation and oxidative stress as well as advanced glycation end products (AGEs) are reported as the risk factors for DN. Sevelamer has shown promising results in reducing inflammation and even HbA1c levels in DN. Objectives: We aimed to evaluate the therapeutic effects of sevelamer on blood sugar, HbA1c level, lipid profile, and high sensitivity C-reactive protein (hs-CRP) in patients with DN. Patients and Methods:In this clinical trial, 18 patients (5 males and 13 females with mean age of 61.22±9.32 years) with stages 2-4 of DN were recruited. Patients were administered with 800 mg of sevelamer twice a day for 3 months. Blood sugar, HbA1c, hs-CRP, lipid profile and other laboratory findings were measured before and 1, 2 and 3 months after initiation of the treatment.Results: There was a significant decline in HbA1c (P = 0.001), postprandial blood sugar (P <0.001) and phosphorus (P < 0.001) at the end of the study period. Sevelamer had no effect on fasting blood sugar, lipid profile, blood urea nitrogen (BUN), creatinine, Na, K and hs-CRP. Conclusions: Our results indicated that along with its phosphorus reducing effects, sevelamer plays an important role in decreasing postprandial blood sugar and HbA1c level. Sevelamer had no effects on lipid profile and hs-CRP.

show abstract

Beneficial effect of lycopene on anti-diabetic nephropathy through diminishing inflammatory response and oxidative stress

2015

View full text Add to dashboard Cite

Lycopene is widely used for nutritional supplementation, but the potential benefits in diabetic nephropathy (DN) remains unknown. This study aimed to highlight the therapeutic prospect of lycopene against streptozotocin (STZ)-induced kidney injury in mice. During the process of the experiments, biochemical kits were employed to determine the diabetes-metabolic parameters in STZ-lesioned mice. Routine pathological and ultrastructural observations were screened for the histological changes of kidney tissue. Moreover, immunohistochemical staining was used to investigate the inflammatory conditions expressed in kidney tissue. Furthermore, intrarenal heme oxygenase 1 (HO-1) mRNA level was assayed via RT-PCR and Western blot analyses. The results showed that lycopene alleviated the lesioned signs of DN mice induced by STZ, accompanied with the increase in body weight, reduced serum concentrations of blood sugar and low-density lipoprotein cholesterol (LDL-C), elevated high-density lipoprotein cholesterol (HDL-C) level, and the decrease in urine protein content. In addition, oxidative defense patterns in the kidneys of DN mice were ameliorated, as shown in augmented bioactivities of superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) and in turn lowered malondialdehyde (MDA) content. The immunohistochemical experiment exhibited that lycopene intake contributed to attenuation of nuclear factor-kappa B (NF-κB) and tumor necrosis factor alpha (TNF-α) expressions in kidney tissue. Moreover, intrarenal HO-1 level was up-regulated in the presence of lycopene. Our findings provide the evidence that lycopene protects kidney cells from STZ-induced lesions via inhibiting NF-κB signal pathway for anti-inflammation and attenuating oxidative stress for anti-dysmetabolism.

show abstract

Néphropathie diabétique : traitements émergents

Cited by 3 publications

References 54 publications

Coadjuvants in the Diabetic Complications: Nutraceuticals and Drugs with Pleiotropic Effects

Coadjuvants in the Diabetic Complications: Nutraceuticals and Drugs with Pleiotropic Effects

The Therapeutic Effects of Sevelamer on Blood Sugar, HbA1c, Lipid Profile, and hs-CRP in Patients with Diabetic Nephropathy

Beneficial effect of lycopene on anti-diabetic nephropathy through diminishing inflammatory response and oxidative stress

Contact Info

Product

Resources

About